Log In
BCIQ
Print this Print this
 

subcutaneous semaglutide (NN9535)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionLong-acting glucagon-like peptide-1 (GLP-1) analog
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentRegistration
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/10/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today